Regeneron Reports Positive Results for EYLEA HD in wAMD Study

Regeneron Pharmaceuticals announced positive results for EYLEA HD in a three-year study, maintaining visual gains in wAMD patients. This positive development may affect investor confidence and stock performance.

Date: 09-02-2025

AI Rating: 7

Positive Phase 3 Results
Regeneron Pharmaceuticals Inc. (REGN) reported positive three-year results from the Phase 3 PULSAR trial for EYLEA HD in patients with wet age-related macular degeneration (wAMD). The results indicate that the majority of patients maintained visual gains and anatomic improvements achieved in previous years, along with longer treatment intervals.

Additionally, patients who switched from the previous injection version were able to sustain vision improvements with fewer injections, showcasing the efficacy of the treatment. These developments suggest not only a competitive edge in the market but also potential for increased sales, thereby possibly improving future revenue growth.

This successful three-year data confirms the robustness of EYLEA HD's efficacy, enhancing investor sentiment towards Regeneron. Positive trial results like these are essential for maintaining and possibly boosting stock prices, as they underline the company's innovation and market viability.

Stocks: REGN